Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_assertion type Assertion NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_head.
- NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_assertion description "[It is important to evaluate the effects of proposed interventions to reduce the risk of disease among carriers of a highly penetrant mutation, such as the mutations in BRCA1 and BRCA2 for breast and ovarian cancers or in APC and MLH1 or MSH2 for colon cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_provenance.
- NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_assertion evidence source_evidence_literature NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_provenance.
- NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_assertion SIO_000772 15316055 NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_provenance.
- NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_assertion wasDerivedFrom befree-2016 NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_provenance.
- NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_assertion wasGeneratedBy ECO_0000203 NP456366.RA0brkV-_YzAhOU5wmeiaGb66k4aubxpubxWYJ0JxxdWk130_provenance.